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A prominent mechanism of acquired resistance to BRAF inhibitors in BRAFV600-mutant melanoma is associated with the
upregulation of receptor tyrosine kinases. Evidences suggested that this resistance mechanism is part of a more complex
cellular adaptation process. Using an integrative strategy, we found this mechanism to invoke extensive transcriptomic,
(phospho-) proteomic and phenotypic alterations that accompany a cellular transition to a de-differentiated, mesenchymal
and invasive state. Even short-term BRAF-inhibitor exposure leads to an early adaptive, differentiation state
change—characterized by a slow-cycling, persistent state. The early persistent state is distinct from the late proliferative,
resistant state. However, both differentiation states share common signaling alterations including JUN upregulation.
Motivated by the similarities, we found that co-targeting of BRAF and JUN is synergistic in killing fully resistant cells; and
when used up-front, co-targeting substantially impairs the formation of the persistent subpopulation. We confirmed that
JUN upregulation is a common response to BRAF inhibitor treatment in clinically treated patient tumors. Our findings
demonstrate that events shared between early- and late-adaptation states provide candidate up-front co-treatment targets.
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Introduction
Advanced metastatic melanoma is a cancer with
traditionally poor treatment options [1]. However, in
2002, BRAFV600E was discovered as a common mela-
noma oncogene that is detected in approximately 50%
of patients [2, 3]. This led to the development and
eventual FDA approval of the BRAF inhibitor
vemurafenib/PLX4032 and dabrafenib/GSK2118436
for patients with advanced melanoma [4–7]. These
BRAF inhibitors induce an objective response rate
beyond 50% but are limited by a median duration of
response of 6–7 months [6]. As with other cancer
therapies, intrinsic, adaptive and acquired resistance
pose major challenges toward further clinical benefits
of BRAF inhibitors [8].
The various reported BRAF inhibitor resistance
mechanisms help to explain the continuum of
evolutionary processes underlying intrinsic, adaptive
and acquired resistance. These include genetic
alterations that reactivate MAPK signaling such as
NRAS mutations [9], MEK mutations [10] or mutant
BRAF amplification [11], which clearly account for
acquired or late clinical resistance [12]. Other resistance
mechanisms that involve upregulation of receptor
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tyrosine kinases (RTKs) and a potential rebalancing of
signaling toward the PI3K/AKT axis likely account for
early resistance associated with intrinsic or adaptive
processes [12]. These RTK alterations include IGF1R
activation [13], overexpression of PDGFR-beta
(PDGFRB), EGFR [12, 14] and potentially
other RTKs (RTK-associated resistance mechanism;
[9, 14–16]). In addition, melanoma cells can show an
early adaptive response to vemurafenib treatment
with subpopulations undergoing cell death induction
or growth arrest [17, 18], preceding proliferative
resistance. This persistent survival state capable of later
proliferation may function as a reservoir for late,
acquired resistance formation driven by genetic
selection [12].
For other cancer types, systems-wide resistance
programs have been identified, which reflect complex
signaling and phenotypic alterations accounting
for intrinsic or adaptive drug resistance. Most promi-
nently, the transition from an epithelial to a mesench-
ymal differentiation state (EMT) has been reported for
various cancers [19–21]. Although mainly thought to
provide cancer cells with a more invasive phenotype,
EMT has been also directly linked to cancer drug
resistance [22–27]. An EMT-like transition has been
reported to contribute to melanoma metastasis [28]
and, in general, melanoma cells show a high level of
differentiation state plasticity [29–32]. Initial reports
on the RTK-resistance mechanism implicated upregu-
lation of RTKs such as PDGFRB, IGF1R and MET
[9, 13, 33]. However, a more complex cellular adapta-
tion to vemurafenib treatment was indicated both by
these initial studies and by subsequent reports [34, 35].
For instance, other RTKs such as EGFR and AXL are
also upregulated [36, 37], upregulation of RTKs shows
temporal dynamics, and pharmacological inhibition of
single RTKs, such as PDGFRB, is not fully effective in
impeding resistance. Moreover, the resistant cells show
morphological alterations such as a flatter and
fibroblast-like appearance. These spindled and pro-
liferative resistant melanoma cells are often found to be
derived from short-term adapted, persisted cells that
survived the stress of BRAF inhibition.
Here using (phospho-) proteomic profiling, we
further characterize the extent to which the observed
temporal dynamic of RTK upregulation, morphologic
switches and cell cycle adaptations are components of a
complex and large-scale adaptation program and
investigate the evolution of these resistant cells using
an integrative proteomic and genomic approach. In
systems-level comparisons, we find the early- and late-
adaptive states to be distinct, but to share common
signaling alterations. Motivated by the similarities, we
demonstrate that targeting an event shared between the
adaptation states, JUN upregulation, can provide an
effective up-front co-treatment strategy against the
adaptive response.
Results
RTK-associated resistance displays extensive proteomic
alterations in cell attachment and cytoskeleton signaling
that are associated with a more mesenchymal state
To gain further insights into a previously
reported BRAF inhibitor resistance mechanism that
involves upregulation of RTKs including PDGFRB
(RTK-associated resistance mechanism; [9]), we com-
pared the signaling network states of two melanoma
cell subline pairs of parental (P) and derived
resistant (R) cells (M229P/R and M238P/R). We used
previously established and validated, quantitative,
mass-spectrometry-based phospho-profiling procedures
[38–41]. First, we focused on phospho-tyrosine
signaling using a pan-specific anti-phospho-tyrosine
enrichment procedure (Supplementary Figure S1 and
Supplementary Table S1). We only identified a
limited number of significantly altered tyrosine-
phosphorylation sites, which included upregulated
phosphorylation of focal adhesion components
(paxillin (PXN)) and caveolin (CAV1) in the resistant
cells. The lack of a more global increase in phospho-
Tyr signaling was initially unexpected for an
RTK-associated resistance mechanism, but confirmed
by western blot (Supplementary Figure S2), and further
motivated a more global analysis of this resistance
mechanism. For this, we used a complementary
phospho-profiling procedure, in which titania material
enriches for peptides phosphorylated on serine,
threonine or tyrosine (Figure 1a, Supplementary
Figure S1, Supplementary Table S2). Importantly,
both cell line pairs showed high correspondence
between the observed signaling alterations (Figure 1b,
Supplementary Figure S3). Upregulated signaling
events in the resistant cells included phosphorylation
of JUN (pS63; [42]), and phosphorylation of the
RAS-family member RRAS2 (pS192). Signaling
events upregulated in resistant cells were significantly
enriched for cytoskeletal components (Figure 1a,
Supplementary Table S2). Visualization of a functional
interaction network for the observed signaling altera-
tions highlights several perturbed signaling processes,
most prominent of which included signaling perturba-
tions in cytoskeleton and cell attachment processes
(Figure 1c).
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Figure 1 Proteomic analysis of the global signaling state of melanoma cells with RTK-resistance mechanism reveals extensive
alterations in cell attachment and cytoskeleton-related signaling processes. (a) Global phospho-profiling of two parental
(P)/resistant (R) cell line pairs of the RTK-resistance mechanism (M229P/R and M238P/R; vem = 6 h treatment with 1 μM
vemurafenib/PLX4032 (vem)). Each column of the heatmap represents a phospho-peptide. The fold change of phosphorylation
compared with the respective parental cell line is color coded in shades of red (upregulated in resistant cells) or green
(downregulated in resistant cells). The phospho-profile was generated with a quantitative, label-free mass-spectrometry
technique established in our laboratory [38]. (b) Significantly altered phosphorylation sites show same trend in both cell line
pairs. A highly significant association between the direction of change for the M229 and M238 pair is observed (Fisher’s exact
test; P-value o2.2 × 10− 16). See Supplementary Figure S3 for more details. (c) Illustrative functional protein network of
differentially regulated phospho-proteins highlights the observed alterations in cytoskeleton and cell attachment processes in
RTK-resistance mechanism cells. The node core and border color shows phosphorylation and gene expression regulation (see
legend; darker shades indicate stronger deregulation; missing values are gray). Gene expression data are from Nazarian et al.
([9]; geometric mean of fold changes for M238R/P and M229R/P). The network was generated with the Reactome FI plugin in
Cytoscape [94]. The Reactome FI database combines curated interactions from Reactome and other pathway databases with
statistically filtered uncurated pairwise relationships from various sources including protein interaction and gene co-expression
data sets. Phospho-proteins significantly altered in RTK-resistance mechanism supplemented with differentially regulated genes
were linked by functional interactions from the Reactome FI database (network edges). The clusters were identified manually,
guided by computational analysis [95].
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To investigate whether the observed global
alterations in cell attachment processes are accom-
panied by alterations in the extracellular context of
these cells, we compared the extracellular matrix
(ECM) secreted by the two parental/resistant cell line
pairs (Figure 2a, Supplementary Table S3). The ECM
of the resistant cells showed a striking increase in
collagen alpha-1 chain type I (COL1A1), fibronectin
(FN1), thrombospondin 1 (THBS1), perlecan
(HSPG2) and matrilin 2 (MATN2). Interestingly, all
five proteins have been previously associated with a
mesenchymal differentiation state [43–45]. Moreover,
PDGFRB expression itself, the initial hallmark of the
analyzed resistance mechanism, is a marker for
mesenchymal cells [46].
These findings, together with the previously noted
morphological changes of the resistant cells (flatter,
larger and more fibroblast-like; [9]), motivated us to
further test whether the RTK-resistance mechanism is
associated with a differentiation state change to a more
mesenchymal state. To this end, we evaluated more
systematically the expression pattern of mesenchymal
marker genes in the resistant cells (Figure 2b; [47]).
Both RTK-resistance mechanism cell lines (M229R
and M238R), but not an NRAS-resistance (MAPK
reactivation) mechanism cell line (M249R), demon-
strate a significant upregulation of mesenchymal
marker genes including collagen alpha-1 chain type I
(COL1A1), fibronectin (FN1) and alpha smooth muscle
actin (ACTA2). This is further corroborated by the
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Figure 2 RTK-resistance mechanism melanoma cells are shifted to a mesenchymal de-differentiation state. (a) Proteomic
profiling of the extracellular matrix (ECM) components of two parental/resistant cell line pairs with RTK upregulation. Heatmap
representation of significantly altered ECM components (false discovery rate o0.1) ordered by the signed t-test of differential
expression between resistant and parental cells. The color-coded ‘expression values’ were calculated as the median of all mean-
centered peptide quantification values for a given protein (see 'Materials and Methods' section). Proteins labeled with ‘m’ have
been associated with mesenchymal expression, previously (see the main text). (b) Upregulated genes in RTK-resistant
melanoma cells (M229R, M238R) are enriched for mesenchymal signature genes. Gene expression signatures ranked by fold
change for two parental/resistant cell line pairs with RTK upregulation (M229R/P, M238R/P and their sum) were assessed for the
enrichment of mesenchymal signature genes (identified by Cheng et al. [47]). Both RTK-upregulated resistant cells (M229R and
M238R), but not the NRAS-mutated resistant cell line (M249R), show significant enrichment of mesenchymal signature genes
among the overexpressed genes (Po0.001). (c) Direct comparison of RTK-upregulated resistant cell signature (log fold change
sum of M229R/P+M238R/P) with mesenchymal (stem cell) signature derived from a global gene expression data set [50].
Comparison with the rank–rank hypergeometric overlap (RRHO) algorithm [92] shows a significant overlap between genes
upregulated both by the resistant melanoma cells and by mesenchymal cells. (d) Western blot for expression of select marker
genes. M249P and M249R cells (NRAS-resistance mechanism) were included for comparison. See Supplementary Figure S4 for
additional comparisons between the RTK and NRAS mechanisms. RTK, receptor tyrosine kinase.
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significant enrichment of ‘mesenchymal’ gene sets
from the CCancer database in the RTK-mechanism
gene expression signature (Supplementary Table S4;
[48, 49]). Furthermore, we directly compared the
RTK-resistance mechanism gene expression signature
with a mesenchymal expression signature from a
published global map of human gene expression
(Figure 2c; [50]). Again, a highly significant overlap of
the genes upregulated in the RTK-mechanism sig-
nature and the mesenchymal signature genes supports
that the resistant melanoma cells are in a state
that strongly resembles mesenchymal cells. Finally,
to further validate the differentiation state change of
the RTK-resistant cells toward a more mesenchymal
state, we confirmed the expression of select marker
genes (PDGFRB, FN1 and ACTA2) at the protein
level (Figure 2d).
RTK-resistance mechanism resembles the invasive
phenotype associated with a common de-differentiation
state in melanoma
Having established that the RTK-resistance
mechanism cells have undergone a transition to a
more mesenchymal state, which is reminiscent of an
epithelial to mesenchymal transition in other cancer
types, we investigated the relation of this process with
known melanoma biology. On the basis of overlapping
marker genes and proteins (for example, FN1
upregulation andMITF downregulation), we identified
a biological similarity to a reported phenotypic switch
in (BRAF inhibitor-naive) melanoma, as reported
in a series of publications by Hoek, Dummer and
colleagues. Here, melanoma cells transition between a
‘proliferative’ and an ‘invasive’ state [29–32]. Notably,
the gene expression signature of the RTK-resistance
mechanism highly overlaps with the ‘invasive
phenotype’ signature (Figure 3a; [30]). This was further
confirmed by a more extensive pairwise rank-based
correlation analysis of RTK-mechanism, phenotypic
switch and negative control signatures (Figure 3b).
This similarity is also apparent on the level of
individual marker genes (Figure 3c). Note that
upregulation of RTKs (EGFR and PDGFRB) is a
component of the ‘invasive’ phenotype signature. Thus,
these two transition processes—resistance formation
upon exposure to BRAF inhibitors and the more
stochastic melanoma phenotypic switch—highly
overlap.
These gene expression similarities predict similarities
in the resulting phenotypes. Phenotypes reported for
the ‘invasive’ state include increased invasion and
formation of tubuli-like structures on Matrigel and
other alterations in cell attachment and migration
processes [30, 31]. We tested these phenotypes for the
two cell line pairs and found similar phenotypic
alterations for the RTK-resistance mechanism cells:
increased tubuli-like structure formation on Matrigel
(Figure 3d), increased cellular clustering/sphere
formation (Figure 3e), increased invasion through
Matrigel (Figure 3f) and stronger attachment
(Figure 3g). In contrast, the NRAS-mechanism M249
parental/resistant cell line pair does not show a
corresponding increase in mesenchymal markers
including FN1, ACTA2 and PDGFRB nor an
induction of tubuli-like structure formation (Figure 2d,
Figure 3c and Supplementary Figure S4). Hence, the
RTK-associated resistance mechanism involves an
extensive differentiation state switch to a more
mesenchymal and ‘invasive’ state.
BRAF inhibition-induced early adaption persistent cells
demonstrate a distinct de-differentiation state compared
with long-term adaptation
Having documented that long-term adaptation
to vemurafenib treatment (that is, full resistance
formation) engages a complex differentiation program,
we asked how this long-term adaptive state compares
with the short-term adaptive state of vemurafenib-
treated melanoma cells. We and others have observed
that melanoma cell lines treated with vemurafenib
show only limited cell death concomitant with
persistence of a slow-cycling subpopulation (Figure 4a,
Supplementary Figure S5; [12, 17, 18, 35, 51]). This
persistent cell subpopulation is thought to constitute
a reservoir for the development of subsequent
proliferative resistance [12, 18, 51].
Whole-proteome profiling and clustering demon-
strated that the persisting cells are themselves in a
distinct cellular state compared with both the parental,
drug-naive cells and the chronically drug-exposed,
proliferative resistant cells (Figure 4b, Supplementary
Figures S6 and S7, Supplementary Table S5). Not
surprisingly, the persistent state was clearly marked by
the growth arrest-coherent downregulation of several
translation-, metabolism- and cell cycle-related pro-
teins. In addition, the persistent state was characterized
by elevated expression of several melanoma
de-differentiation marker proteins such as NGFR/
CD271, ALCAM/CD166 and S100B: NGFR has been
identified as a presumptive marker for melanoma-
initiating/tumor stem cells [52], a neural-crest cell
marker for desmoplastic and neurotropic melanomas
[53] and a marker for immunotherapy-resistant,
de-differentiated melanoma cells [54]; ALCAM was
Bjoern Titz et al.
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identified as a melanocytic stem cell marker, which
shows higher expression for melanomas than banal
nevi [55, 56]; and S100B has been associated with dis-
ease stage, reduced survival, metastases and treatment
response [57]. Validation experiments for cell surface
expression of NGFR/CD271 by flow cytometry
demonstrated high upregulation in persisting cells, but
even downregulation for one of the resistant cell lines
(M238R; Figure 4c and d). In reverse, markers for the
resistant state (PDGFRB and FN1) were not or were
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only slightly elevated in the persistent state (see below).
In summary, although both long-term and short-term
adaptation involve a differentiation state change, these
states are distinct.
To gain insights into the signaling alterations
occurring upon short-term BRAF inhibitor exposure
and resulting in the persistent population—and to
subsequently compare these with the fully resistant
state—we conducted an additional global phospho-
profiling experiment on three parental vs early drug-
persistent pairs (from the aforementioned M229 and
M238 parental lines as well as another BRAF inhibitor
sensitive line M249; Figure 4e, Supplementary
Figure S6, Supplementary Table S6). Persistence
formation resulted in a distinct signaling state—with a
higher consistency for the M229P and the M238P pairs
than for the M249P pair (Supplementary Figure S8).
Again, many downregulated phosphorylation sites,
total proteins and the predicted downregulation of
CDK1/2 signaling logically reflected the growth-
downregulated state of the persistent cells, for
example, downregulation of phosphorylated transla-
tion factors, metabolic enzymes and cell cycle proteins
(Figure 4e, Supplementary Table S6). Several
phosphorylation sites were consistently upregulated in
the persistent cells, including PKC-alpha (PRKCA),
NOTCH2, SP3 and Catenin Alpha-1 (CTNNA1).
Although overall distinct, the early persisting
subpopulation shares particular signaling alterations
with the proliferative resistant state
The short-term adaptation persistent cells are in an
overall distinct cellular state with a different set of
signaling alterations. However, we questioned whether
long- and short-term adaptation to vemurafenib
treatment share any signaling alterations that could
potentially guide the identification of (co-) treatment
approaches that prevent and/or target adaptive
responses. To this end, we ranked the signaling
alterations by a combined perturbation score
incorporating the measured changes in the two fully
resistant and two persistent cell line pairs (Figure 5a,
Supplementary Table S7). The shared upregulated
signaling events include PKC-alpha (PRKCA, pT497),
JUN (pS63), progesterone receptor membrane
component 1 (PGRMC1, pS57 and pS54), and tumor
suppressor p53-binding protein 1 (TP53BP1, pS500
and pS380). Note that phospho-JUN upregulation was
initially only detected in the resistant pairs, but clear
evidence of its upregulation in the persistent cells was
also obtained through a targeted analysis of the mass-
spectrometry data set (Supplementary Figure S9) and
by western blotting (Figure 5d)—for both the S63 and
the S73 site of JUN (Supplementary Figure S10B). For
both PKC-alpha and the transcription factor JUN, our
data and analysis provided multiple lines of evidence
implicating their role in the BRAF inhibitor adaptive
states. In addition to its increase in net phosphorylation
levels, JUN is transcriptionally upregulated in the
resistant and the ‘invasive phenotype’ melanoma cells
(Figure 3c). Moreover, a transcription factor binding
site enrichment analysis of the RTK-resistance
mechanism gene expression data predicted higher
JUN activity for the resistant cells (Figure 5b and
Supplementary Table S8). In the case of PKC-alpha,
the kinase enrichment analysis of our phosphorylation
data set implicated a higher PKC kinase activity
(Figure 5c).
Figure 3 The RTK-resistance de-differentiation mechanism closely resembles the melanoma phenotypic switch. (a) Significant
similarity of the Hoek–Dummer and RTK-mechanism gene expression signatures. Differentially expressed genes in cell lines with
RTK-mechanism of resistance (M229R and M238R)—vs their parental lines (M229P and M238P)—were ranked by their sum fold
change difference (black bars). The locations of genes upregulated (red lines, ‘invasive phenotype’) or downregulated (green lines,
‘proliferative phenotype’) by the Hoek–Dummer switch phenomenon (invasive phenotype) are indicated. A significant enrichment of the
Hoek–Dummer signature genes is seen at the far ends of the RTK-mechanism distribution (permutation P-value o10–4). (b) Clustered
correlation matrix shows similarity of RTK-mechanism cells and ‘invasive phenotype’ cells (Hoek–Dummer switch phenomenon).
Pairwise Pearson correlation coefficients were calculated for nine gene signatures and clustered using a hierarchical clustering
procedure. These included three RTK-mechanism-related signatures (M229 (resistant vs parental), M238 (resistant vs parental), M229
+M238 (both RTK-mechanism signatures combined)), three different phenotypic switch signatures (Mannheim, Philadelphia and Zurich;
‘invasive’ vs ‘proliferative’ phenotype; [4]), and three control signatures (Blothner (CDKN2A status); [25]), Joseph (PLX4032 treatment;
[26]), and M249 (NRAS-based resistance mechanism; [2]). (c) Selected expression differences for the RTK-mechanism, phenotypic
switch and control gene signatures. The log2 fold change difference is color coded (red, upregulated in resistant or invasive cells; green,
downregulated). (d) Both parental/resistant cell line pairs show a phenotypic switch in the tubuli-formation assay. (e) The resistant cells
form a dense cell cluster in a sphere formation assay. (f) Resistant cells show increased migration through Matrigel in a transwell invasion
assay. (g) Resistant cells demonstrate slower detachment when treated with trypsin/EDTA (percent detached after 3 min). EDTA,
ethylenediaminetetraacetic acid; RTK, receptor tyrosine kinase.
Bjoern Titz et al.
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We further confirmed the Jun and PKC signaling
alterations by western blot (Figure 5d). Upregulation
of JUN and phospho-JUN is observed in an expanded
panel of three resistant sublines with RTK-associated
resistance but not in an alternate subline with mutant
NRAS-driven resistance (M249R). Similarly, we
observed alteration in the pattern of PKC isoform
phosphorylation and upregulation of a single PKC
isoform associated only with the RTK-resistance
mechanism using the same set of cell line pairs. We
confirmed that the resistance mechanism results speci-
fically in upregulation of the PKC-alpha isoform using
a knockdown strategy (Supplementary Figure S10A).
We classified this phenomenon as a PKC isoform
switch, as from three detectable isoforms only
phosphorylation of PKC-alpha is strongly induced.
Both the JUN and PKC signaling alterations are also
detected in the early persistent cellular subpopulations
(Figure 5e and Supplementary Figure S10B).
Next, we tested whether the cell cycle down-
regulation, as well as JUN and PKC signaling
responses to short-term BRAF inhibitor treatment are
common. We treated three additional BRAFV600E-
positive melanoma cell lines with vemurafenib and
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Figure 4 BRAF inhibition-induced early adaption persistent cells demonstrate a distinct de-differentiation state compared with
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NGFR/CD271 for the persistent populations). Two parental melanoma cell lines (M229P and M238P) left untreated or were
treated with 1 μM vemurafenib (vem) for 6 days (6d), and the corresponding long-term resistant cells (M229R and M238R), were
profiled by quantitative mass spectrometry for proteome expression differences. For the heatmap representation the data was
filtered for an analysis of variance P-value o0.05 and an average 3-fold up- or downregulation between the persistent and
parental cell lines. Representative proteins in gene ontology groups discussed in the manuscript are indicated. (c, d) Flow
cytometry confirms upregulation of NGFR/CD271 in the short-term persistent state for M229 (c) and M238 (d) cells. (e) Profiling of
phospho-signaling alterations in the persistent cell populations. Three parental melanoma cell lines (M229P, M238P and M249P)
were left untreated or were treated with 1 μM vemurafenib for 6 days (+vem(6d)) and phospho-proteome alterations were profiled
by quantitative mass spectrometry. Data were filtered for a significant phosphorylation difference in the parental and short-term
persistent populations (BH-corrected, Student’s t-test-based false discovery rate o0.2; and 2-fold up- or downregulation).
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found that each and every persistent cell population
(Figure 5f) displayed consistent upregulation of JUN
and phospho-JUN upon short-term BRAF inhibitor
exposure. In contrast, the PKC isoform switch was
observed in half of the lines (Figure 5g). To validate
that these responses are on-target effects of vemur-
afenib, we repeated these experiments with dabrafenib,
an alternative FDA-approved BRAF inhibitor ([7, 58];
Figure 5h). Both BRAF inhibitors show the same
effects on both JUN upregulation and the PKC iso-
form switch. In addition, we find that the observed
response is present for BRAF-mutated, but not NRAS-
mutated melanoma cells, supporting these responses as
on-target effects of the BRAF inhibitors (Figure 5i).
Co-targeting mutant BRAF signaling and JUN function
results in synergistic death and diminishes the persistent
cell reservoir
With JUN upregulation and the PKC isoform
switch as shared signaling alterations between the
early persistent, survival and later, proliferative drug-
resistant states, we next asked whether these alterations
are optimal co-treatment targets. As initial experi-
mentation showed that JUN knockdown, but not
PKC-alpha knockdown, was effective in a vemurafenib
co-treatment experiment, we focused our further efforts
in this study on JUN (Supplementary Figure S11). Of
note, in future studies, it will be pertinent to combine
isoform-specific activity and substrate measurements to
reveal the functional role of the PKC isoform switch.
JUN knockdown by itself only minimally affected
untreated parental melanoma cells (Figure 6). In strong
contrast, JUN knockdown induced substantial and
significant death in our panel of both resistant cell lines
and short-term vemurafenib-treated (that is, persistent)
cultures (Figure 6a–d). Of note, the kinetics of JUN
upregulation impacts the optimal sensitivity window
for JUN knockdown: M229P cells show slower JUN
upregulation (Figure 5e) and accordingly are most
effectively co-targeted after longer vemurafenib
pre-treatment (Figure 6b). Consistent with the death
assays, in co-treated resistant and persistent cultures,
we observe synergistic induction of apoptosis markers
(Figure 6e–l). Note that we had selected the different
timings for these experiments to accommodate for the
different biological response times of the phenotypic
effects on cell viability and apoptosis induction, as well
as the response kinetics of the JUN knockdown
procedure. Although there was a degree of expected
cell line heterogeneity, overall, JUN siRNA knock-
down had a significant effect on cell viability both for
the panel of resistant (P-value = 4E− 6) and persisting
cells (P-value o2E− 16) and significantly induced
apoptosis in the resistant/persisting cell line panel
Figure 5 Shared signaling alterations of the short-term persistent (early adaption) and fully resistant (late adaption) cell populations include
JUN upregulation and a PKC isoform switch. (a) Selection of shared phosphorylation events based on summed effect ranking.
Phosphorylation sites were ranked by their summed signed log t-test values for the two resistant/parental and the two persistent/parental
pairs (data collapsed on proteins by largest absolute sum). Among the top proteins, JUN and PKC were selected for follow-up investigations.
Note that phospho-JUN upregulation was initially only detected for the resistant pairs, but evidence for its upregulation was obtained through
a targeted analysis of the mass-spectrometry data set (Supplementary Figure S9). (b) Transcription factor (TF) activity analysis shows
upregulation of JUN activity in receptor tyrosine kinase (RTK)-resistance mechanism cells. Genes were ranked by their fold change
expression difference in parental vs resistant melanoma cells. Gene-set enrichment analysis (GSEA) was conducted to identify enriched
transcription factor binding sites (MSigDB database c3). The results were filtered for binding sites specifically enriched for M229P/R5 and
M238P/R1 (false discovery rate (FDR) o0.1), but not for M249P/R4 (FDR40.2). Normalized enrichment scores (NES) for significance
filtered TF binding sites are shown (sorted by the sum of the NES for M229 and M238). See Supplementary Table S8. (c) Kinase enrichment
analysis points to upregulated kinase activities in RTK-resistance mechanism cells. These include Akt1, ILK and PKC-alpha (PKCA).
Phospho-peptides were ranked by their mean fold change in resistant to parental cells and upregulated kinase activities were identified
(filtered for a FDR (BH-adjusted P-value) o0.2). See Supplementary Table S2. (d) Western blot confirmation of (phospho-) JUN
upregulation and the PKC isoform switch in RTK-resistance mechanism cells (M229R, M238R, SKMEL28R), but not in an NRAS-mutated
resistant cell line (M249R). (e) Short-term vemurafenib-treated, persisting cells share alterations in JUN and protein kinase C (PKC) signaling
with fully resistant melanoma cells. M229P and M238P were left untreated (− ) or treated with 1μM vemurafenib/PLX4032 (vem) for 3 h, 16 h
and 6 days and compared by western blot with the fully resistant cells (M229R and M238R). Short-term vemurafenib-treated cells share the
upregulation of (phospho-) JUN and a PKC isoform switch with the fully resistant state. (f) An extended set of five parental melanoma cell
lines demonstrates a persistent cell population after a 6- day treatment with 1 μM vemurafenib. The percent viable cells vs number of cells
initially plated (dashed line) and the percent viable cells vs cells left untreated and cultured for 3 days (bars) is shown (n =3). (g) Western blot
shows shared signaling alterations upon 6-day 1 μM vemurafenib treatment in these melanoma cell lines. (Phospho-) JUN upregulation is
shared by all cell lines; the PKC isoform switch is most prominent for vemurafenib-treated M229P, M395P and M397P cells. (h) Vemurafenib
(PLX) and dabrafenib (Dabra) treatment induce similar alterations of JUN and PKC signaling. Western blot of M238P and M229P melanoma
cells treated for 6 days with vemurafenib or dabrafenib. (i) BRAF, but not NRAS-mutated melanoma cells show (phospho-) JUN upregulation
upon 6-day vemurafenib (vem) treatment.
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Figure 6 Co-targeting mutant BRAF signaling and JUN function results in synergistic death and diminishes the persistent cell
reservoir. (a–d) Effect on cell viability of 1 μM vemurafenib and JUN short interfering RNA (siRNA) knockdown co-treatment for
parental (P), fully resistant (R), up-front co-treated (+vem(3d)), and short-term persisting cell (+vem(6d)). Viable cells were counted by
Trypan-blue staining with a ViCell counter. A JUN siRNA pool was used for the experiments in this figure, see
Supplementary Table S12 for confirmation with individual siRNAs and Supplementary Table S13 for confirmation with distinct
JUN short hairpin RNAs (shRNAs). (e–h) Induction of apoptosis (Caspase-3/7 activation) in melanoma cells co-treated with 1μM
vemurafenib and JUN siRNA. (i–l) Western blot of melanoma cells co-treated with 1μM vemurafenib and JUN siRNA. PARP cleavage
is shown as an apoptosis marker. Phospho-JUN was included for M249P cells owing to its lower upregulation of total JUN (see
Figure 5g). Significant pairwise differences with a t-test P-value o0.05 are indicated (*). Overall, JUN siRNA knockdown had a
significant effect on cell viability both for the panel of resistant (P-value =4E−6) and persisting cells (P-valueo2E−16) and
significantly induced apoptosis in the resistant/persisting cell line panel (P-value =1E−8), but not in the parental cell line panel (two-
way analysis of variance P-values with JUN siRNA treatment and cell line as factors; significance level α =0.01).
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(P-value = 1E− 8), but not in the parental cell line
panel. Finally, we corroborated the specificity for
JUN in these responses with individual siRNAs
(Supplementary Figure S12) and independent
retroviral-based shRNA constructs (Supplementary
Figure S13). With this, JUN upregulation represents
a signaling alteration shared between the early
adaptation (persistent population) and late adaptation
(proliferative resistance) and that can be effectively
up-front co-targeted to result in synergistic cell death
and diminish the persistent cell reservoir.
In vivo upregulation of JUN in short-term treated
patients and disease progression melanoma biopsies
Finally, we evaluated JUN upregulation in patient
samples. For this, we queried our patient-biopsy
mRNA expression database containing on-treatment
biopsies from four patients and 27 disease progression
biopsies. On-treatment biopsies were obtained
6–22 days after treatment onset and the disease
progression biopsies were obtained from patients on
the progression of disease after the initial progression-
free response (Supplementary Table S9). When
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Figure 7 JUN upregulation is a common treatment response in
melanoma patient samples (a) The occurrence of JUN upregula-
tion on BRAFi treatment in mRNA expression data from 31
biopsies of 14 melanoma patients. The x-axis labels indicate
patient (Pt) and biopsy numbers. Biopsy identification numbers
with a quote symbol (‘) are from tumor(s) treated with BRAFi
+MEKi dual inhibitor therapy. On the left are four on-treatment
biopsies from four patients treated from 6 to 22 days, and on the
right are disease progression (DP) biopsies annotated with their
patient identification number (a total of 27 DP biopsies). The
clinical details of the patients and the biopsied tumors are
presented in Supplementary Table S9. mRNA expression was
quantified by RNAseq except for Pt # 1, 13 and 14 for which exon-
level microarray analysis was used. The JUN mRNA expression
fold changes are computed with respect to each patient’s pre-
treatment tumor JUN expression level. The JUN expression fold
change for each patient is shown with error bars based on
standard error of the mean (SEM) across replicates. Cases of
statistically significant differential expression are indicated by up
(red) and down (green) triangles. JUN was upregulated in two out
of four on-treatment biopsies in two out of four patients and 6 out
of 27 DP biopsies in 5 out of 11 patients. JUN was downregulated
in 8 out of 27 biopsies in 4 out of 11 patients. DP biopsies from Pt
#14 showed multiple cases of downregulation of JUN except for
DP biopsy #9, indicating heterogeneous resistance mechanisms
having a role [12]. Known genetic resistance mechanism identi-
fied in each sample are color coded as indicated in the key based
on Shi et al. [12]. There is a slight enrichment of JUN upregulation
in samples with an unknown resistance mechanism (Fisher’s
exact test; P-value = 0.095). (b, c) JUN immunohistochemistry
staining of the on-treatment biopsy and the disease progression
biopsy from a with substantial JUN mRNA upregulation. (b)
patient #4; day 22 (D22) of kinase inhibitor treatment. (c) patient
#11, biopsy #2, disease progression biopsy #2 (DP2). The
respective baseline biopsies are also shown. JUN protein
expression was visualized with a red chromogen. IHC,
immunohistochemistry.
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compared with baseline JUN expression, two out of
four on-treatment biopsies (two of four patients) and 6
out of 27 disease progression biopsies (5 of 11 patients)
demonstrated significant upregulation of JUN mRNA
levels (Figure 7a). There was a slight enrichment of
JUN upregulation in disease progression samples
that do not harbor an identified MAPK-pathway
reactivation resistance mechanism. JUN protein-
based immunohistochemistry staining of tumor
sections confirmed the mRNA results (Figure 7b
and c). With this, JUN upregulation is a common
response to BRAF inhibitor treatment.
Discussion
BRAF inhibitors including vemurafenib and
dabrafenib, have provided unprecedented benefits for
the treatment of metastatic melanoma [4, 6]. However,
resistance development severely limits the rate and
duration of clinical response to the BRAF inhibitors
[59]. Although only a minority of patients carry tumors
with pre-existing resistance and do not clinically
respond to BRAF inhibitor treatment (intrinsic
resistance), most patients show an initial response
followed by progression with a median time of
6–7 months (acquired resistance). This is because
BRAF inhibitor treatment can leave behind a persis-
tent cell population that does not show full resistance
(for example, shows a low proliferation rate) but serves
as a cellular reservoir for the development of full-blown
proliferative resistance [17, 18].
Several BRAF inhibitor resistance mechanisms have
been identified. These are commonly classified into
mechanisms that either reactivate the MAP-kinase
pathway or mechanisms that activate alternative
pathways such as the PI3K–AKT pathway. Among the
former is the acquisition of secondary NRAS/KRAS
mutations [9, 12] and the expression of a truncated
BRAF variant [11, 60]; among the latter is the
overexpression of PDGFRB [9] or IGF1R ([13];
RTK-associated resistance mechanisms). In addition,
proteins that contribute to early persistence have been
identified, including FOXD3 [61]. These previous
studies have engendered clinical strategies such as
BRAFi+MEKi or BRAFi+AKTi already being tested
(and showing promise) in patients.
Here, we undertook an integrative proteomics/
transcriptomic approach to understand the context and
global alterations associated with resistance formation
to devise novel BRAFi-based combinatorial strategies
to suppress resistance. To this end, we have generated
several quantitative protein, phospho-protein and
ECM-protein expression data sets for different cellular
states (parental, resistant, persistent). A challenge for
the direct integration of the data sets (as seen for JUN
phosphorylation, Supplementary Figure S9) was the
often limited overlap of the detected proteins
(Supplementary Figure S14). Pairwise comparisons
demonstrate that although expected similarities exist,
these data sets are consistent and largely com-
plementary (Supplementary Figure S14). This is
reflected in our integration approach presented here:
rather than a one-shot data generation/integration step,
each data set was generated by considering the previous
insights and conceptually integrating them in a step-by-
step manner to reveal the important factors in the
mechanism of resistance.
At the onset of our study, the available data sug-
gested that the RTK-resistance mechanism [9, 13, 62]
takes place in a broader context of adaptive alterations.
For example, pharmacological inhibition of PDGFRB
by itself is not fully effective, and RTK-associated
resistant cells show striking cellular morphological
alterations [9]. In addition, in the current study, we did
not find evidence for overall increased phospho-Tyr
signaling in these cells (Supplementary Figures S1 and
S2, Supplementary Table S1). Rather, consistent with
other studies [34], we found that RTK-associated
resistant cells express a mesenchymal gene signature
(Figure 2), show extensive alterations in cytoskeleton
and cell attachment-related signaling (Figure 1)
and secrete ECM components that are associated
with a mesenchymal state [43–45]. With this, the
de-differentiation response of the resistant cells is
reminiscent of EMT observed in other cancers
[19, 21, 63]. EMT has been associated with metastasis
formation, which is consistent with the observed
cytoskeletal and invasive phenotype alterations.
Moreover, EMT has been reported as a mechanism of
resistance to kinase inhibitor therapies for several
cancer types including lung, colorectal and breast
cancer [25, 64, 65]. In these cases as well, the
mesenchymal resistance phenotype is thought to
involve a multitude of signaling alterations (for
example, upregulation of several RTKs) rather
than a single gene alteration or mutation [23, 64].
Importantly, PDGFRB upregulation is also a common
component of these mesenchymal transition programs
and its role in migration and resistance has been
reported [66]. Taken together, PDGFRB and RTK
family upregulation, the hallmark alteration of the
analyzed resistance mechanism, is part of a more
extensive EMT-like de-differentiation program that
involves a multitude of signaling changes.
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Differentiation state plasticity has also been
reported before the BRAF inhibitor era—initially and
most extensively in a series of reports by Hoek and
Dummer [29–32]. In these reports, untreated (BRAF
inhibitor-naive) melanoma cells were found to transi-
tion between a ‘proliferative’ and an ‘invasive’ state. In
a direct gene signature comparison, we found a striking
overlap between the resistant/de-differentiation state
and the Hoek–Dummer ‘invasive’ state (Figure 3). The
key feature of ‘invasive’ melanoma cells is their altered
cell attachment and migration phenotype, phenotypes
that we found to be also exhibited by BRAF inhibitor-
resistant cells. In addition, published reports have
demonstrated that MAPK-pathway inhibition in
‘proliferative’ melanoma cells can at least partially
induce phenotypic features of the ‘invasive’ state [31].
Other examples for differentiation state plasticity in
melanoma—with close ties to the resistant/invasive/
mesenchymal state—include vasculogenic mimicry [67]
and acquisition of stem-like properties [68].
Importantly, independent reports support the in vivo
relevance of this mesenchymal de-differentiation state
in BRAF inhibitor-naive melanoma. Bittner et al. [69]
identified a related invasive phenotype cluster using
short-term melanoma cultures. In addition, Lewis et al.
[70] analyzed melanoma patient samples directly by
RT-PCR and identified a cluster of samples that
demonstrates features of the invasive/mesenchymal
phenotype (for example, increased WNT5a, JUN,
EGFR expression). Finally, in recent publications, we
and others reported on the relevance of a closely related
MITFlow/AXLhigh cellular state in melanoma resistance
[36, 37]. With this, the observed differentiation state
and phenotypic alteration of the BRAF inhibitor-
resistant cells complements previous studies and
clearly reflects the common cellular plasticity program
of melanoma cells and tumors. Of note, the link
established here between the de-differentiation and
BRAF inhibitor resistance has also implications for
other undesired outcomes such as the induction of an
enhanced metastasis potential—for example, a recent
retrospective analysis showed an increase in metastasis
formation for patients that failed BRAF inhibitor
treatment compared with dacarbazine treatment [71].
We and others have observed that vemurafenib
treatment induces a slow-cycling, persistent cell popu-
lation [17, 18, 35], which serves as a likely reservoir for
the emergence of fully resistant proliferative cells [18].
On exploring the relationship between the early per-
sistent and the fully resistant state using molecular
profiling, we found the persistent state to be distinct
from the fully resistant state and from the parental
state. Specifically, clustering analysis separated the
states (Supplementary Figure S7); markers for the
resistant state (PDGFRB and FN1) were not or were
only slightly elevated in the persistent state (Figure 5);
and the persistent state showed distinct marker
expression such as NGFR/CD271 (Figure 4). On the
basis of its molecular program, the de-differentiation
persistent state is potentially related to the NGFR/
CD271hi state reported by Landsberg et al. [54] as a
resistance mechanism to adaptive T-cell therapy, and
to the NGFR/CD271hi state of melanoma stem cells
[52, 72], which, however, is still debated [73].
Despite clear differences in the complex changes
associated with the slow-cycling/persistent and resis-
tant states, we asked whether these short-term and
long-term adaptation programs share any potentially
targetable signaling alterations. Among the identified
shared signaling alterations between these states were
JUN upregulation and a PKC isoform switch
(Figure 5). In BRAF inhibitor-naive melanoma, JUN
has been reported as a regulator of tumor progression
and as a potential therapeutic target [74–77]. JUN
upregulation has been associated with melanoma
treatment resistance to classical chemotherapy [78]. In
BRAF inhibitor-resistant melanoma cells, JUN was
characterized as a mediator of upregulated PD-L1
expression [79]. Forced expression of the JUN
binding partner FOS can confer resistance to RAF and
MEK inhibitors [80]. In our study, JUN knockdown
was synergistic with BRAF inhibition in co-treatment
experiments, whereas JUN knockdown in parental
cells had only a minimal effect, it prevented
vemurafenib persistence and significantly decreased
viability of resistant cells (Figure 6). In addition, we
found that JUN upregulation is a common treatment
response in melanoma patient samples (Figure 7).
From this, we conclude that early and late vemurafenib
non-responsive states share signaling alterations that
can be effectively targeted in vitro, and we provide
initial evidence that these alterations are observed
in vivo.
Recently, in support of our finding, Fallahi-Sichani
et al. [81] and Ramsdale et al. [82] have independently
identified the relevance of JNK/c-JUN signaling in the
adaptive response of melanoma cells to vemurafenib
treatment. In our experiments, only JUN knockdown
but not pharmacological JNK inhibition was effective
(Figure 6, Supplementary Figure S15). A similar
observation has been made previously by Spangler
et al. [74]. In the study by Fallahi-Sichani et al.,
a recently developed and improved JNK inhibitor
JNK-IN-8 [83] was effective, whereas the JNK
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inhibitor SP600125 that was used in our study had a
much more limited effect. Considering the strong
inhibitory effect of SP600125 on JUN phosphorylation
(Supplementary Figure S15) and the previously
reported complexity of pharmacological JNK inhibi-
tion [84, 85], the implementation of JNK inhibition
strategies in the clinic warrants a more detailed
understanding of these differences in cellular response.
Despite the breakthrough that BRAF inhibitors
brought to malignant melanoma therapy, major
challenges lie ahead toward more effective and longer
lasting treatments. The complexity of the adaptive
response of melanoma cells—early in the form of per-
sistence and later in the form of full resistance—poses a
major challenge. Our results highlight the role of
differentiation plasticity in the adaptive responses of
melanoma cells. BRAF inhibitor-treated cells undergo
changes far beyond single gene mutations and these
differentiation changes are accompanied by altered
dependencies and treatment sensitivity profiles.
Notably, we identified shared signaling alterations
between the early- and late-adaptive states and found
that up-front co-targeting of BRAF and JUN results in
synergistic killing and thus a marked reduction in
the resistance-enabling persistent state. This result
supports the therapeutic concept that up-front
co-treatment regiments are necessary to overcome
kinase inhibitor resistance and provide the next
advance in genetically informed therapies [86, 87].
Materials and Methods
An extended description of the methods is available in
Supplementary Information.
Cell culture
Melanoma cells were cultured in RPMI with 10% fetal
bovine serum (FBS) and antibiotic-antimycotic (Invitrogen,
Carlsbad, CA, USA). Resistant melanoma cells were cultured in
the presence of 1μM vemurafenib/PLX4032 (ChemieTek,
Indianapolis, IN, USA).
Quantitative proteomics
Tyrosine phospho-profiles were analyzed using a quantitative
mass-spectrometry method as described previously [7, 8].
Briefly, the cells were lysed by sonication in urea lysis buffer
before quantitative analysis of affinity enriched phospho-
tyrosine peptides by mass spectrometry. Relative amounts of
the same phospho-peptide across sample runs were determined
using custom software from our lab that conducts run–run
alignments and integrates the area under the unfragmented
(MS1) monoisotopic peptide peak [38, 39]. Global phospho-
Tyr/Thr/Ser profiles were analyzed as described previously by
quantitative mass spectrometry using a protocol that involves
peptide fractionation by strong cation exchange chromato-
graphy and phospho-peptide enrichment with titania material
[40]. To profile alteration of secreted ECM components, the
melanoma cells were seeded on tissue culture dishes and kept at
high density (full confluence) for 2 days. After a phosphate-
buffered saline (PBS) wash, the cells were detached with 20 mM
NH4OH and the plates were washed four times with PBS. The
ECM components were detached and collected in ECM lysis
buffer (8 M urea, 100 mM NH4HCO3 and 0.1 M DTT). The
samples were processed for mass-spectrometry analysis using an
adapted FASP procedure [88] and quantitative mass spectro-
metry was conducted as described for the phospho-profiling
protocol. For whole-proteome expression profiling, the cells
were washed with PBS, lysed (8 M urea, 50 mM Tris/HCl,
pH = 7.5) and the samples were processed for mass-
spectrometry analysis using an adapted FASP procedure [88].
Peptides were analyzed by liquid chromatography tandem mass
spectrometry as described for the phospho-profiling protocol
and quantified with the Sieve software (version 2.0, Thermo
Fisher Scientific, Waltham, MA, USA).
Mesenchymal and phenotypic switch gene signatures
Expression data for the RTK-resistance mechanism
(GSE24862; [9]) and the reference data sets (GSE4840,
GSE4841, GSE4843, GSE22787, GSE20051; [30, 89, 90]) were
obtained from the GEO repository and processed with R/Bio-
conductor [91]. Similarity to the ‘multi-cancer mesenchymal
transition gene expression signature’ [47] was assessed with a
permutation-based Kolmogorov–Smirnoff non-parametric rank
test. The rank–rank-hypergeometric overlap method was used
to evaluate the similarity with a mesenchymal signature derived
from ‘a global map of human gene expression’ [50, 92].
Attachment and migration phenotypic assays
For the sphere formation assay, wells of a 96-well plate were
coated with 50 μl 1% (w/v) agarose in PBS. A total 15 000 cells
were plated in 100 μl media per well and incubated overnight.
The plate was shaken to distribute non-attached cells evenly
before taking the images. For the detachment assay, 30 000 cells
were plated per well of a 24-well plate and incubated for 2 days.
The cells were PBS washed and trypsin-EDTA was added. After
3 min, RPMI media with 10% FBS was added and the detached
cells were collected. The remaining (attached) cells were quickly
washed with PBS and incubated with trypsin-EDTA until
complete detachment. RPMI media with 10% FBS was added
and the remaining cells were collected. The cells in both fractions
were counted with a ViCell counter (Beckman Coulter,
Indianapolis, IN, USA) and the percentage of cells detached
after 3 min calculated. The tubuli-formation assay on Matrigel
was performed similar to Zipser et al. [31]. Ninety-six-well plates
were coated with 50 μl Matrigel (BD Bioscience, San Jose, CA,
USA) per well. The cells were plated in 100 μl RPMI with 10%
FBS (20 000 cells for M229P/R and 40 000 for M238P/R) and
incubated overnight. The invasion assay was done similar to
Zipser et al. [31]. Briefly, 24-well Transwell inserts (8-μm pore
size, polycarbonate, Corning, Corning, NY) were coated with
Matrigel (BD Biosciences). The cells were plated in serum-free
media into the inserts, and media with 10% FBS were used as a
Bjoern Titz et al.
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chemoattractant. After 24 h, the cells were fixed with PFA and
stained with crystal violet.
Induction of persistent state by BRAF inhibition
Parental (BRAF inhibition sensitive) melanoma cells were
plated at a density of 10 500 cells cm− 2 in media without BRAF
inhibitor. The next day, the media were exchanged and 1 μM
vemurafenib (or the indicated concentration of dabrafenib) was
added. The cells were cultured for 6–7 days with one media
change after 3 days and another 1 day before analysis.
Effects of JUN perturbations
Individual and pooled JUN siRNAs were obtained
from Dharmacon/Thermo Scientific (Waltham, MA, USA)
(siGENOME Human JUN (3725)). The siRNAs were reverse
transfected with Lipofectamine RNAiMAX (Invitrogen).
Lentiviral shRNAs for JUN were obtained from Sigma-Aldrich
(St Louis, MO, USA) (TRCN0000010366, TRCN0000039590)
and lentiviral particles were produced with a standard protocol
(http://www.broadinstitute.org/rnai/public/resources/protocols).
Trypan-blue staining and a ViCell counter was used for viable
cell counting (Beckman Coulter). For MTS-based cell viability
experiments, the CellTiter 96 AQueous One Solution Cell
Proliferation Assay was used (Promega, Madison, WI, USA).
Apoptosis induction was measured by a PARP cleavage western
Blot and by an ApoTox-Glo assay for Caspase-3/7 activation
(Promega).
Analysis of patient samples
The mRNA expression of samples originating from patients
(Pt) #1, 13 and 14 were analyzed using the Affymetrix exon-
based microarray HuGene ST (Affymetrix, Santa Clara, CA,
USA). The samples from patient #1 (three technical replicates
per sample) were analyzed using HuGene ST version 1.0,
whereas the samples from patients #13 and 14 (two technical
replicates per sample) were analyzed using version 2.1. The fold
changes of genes were computed based on log2 RMA-
normalized expression values of the on-treatment samples or
disease progression samples against their respective baseline
(pre-treatment) samples. FDR-adjusted P-value of differential
expression are computed using the limma R package. The
mRNA expression of all the other patients were analyzed by
RNAseq. Each sample was run on two separate lanes in the
Illumina HiSeq 2000 sequencing platform (Illumina, San Diego,
CA, USA) to generate two (technical) replicates per sample. The
fold change of RNAseq samples were computed on the basis of
the ratio of averaged RPKM values of the samples and their
respective baselines. The FDR-adjusted P-value of the RPKM
change are computed using the GFOLD program [93]. Immu-
nohistochemistry was performed using c-Jun antibody #9165
from Cell Signaling Technology (Danvers, MA, USA) at a 1:400
dilution, MACH 2 Rabbit AP Polymer secondary antibodies
(Biocare Medical, Concord, CA, USA, catalog #MALP525)
and a red chromogen (Vulcan Fast Red—Biocare Medical,
catalog #FR805H) with hematoxylin counterstaining.
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